Can the Combination of Incretin Agents and Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors Reconcile the Yin and Yang of Glucagon?

被引：10
|
作者：
Goldenberg, Ronald M. [1 ]
Verma, Subodh [2 ]
Perkins, Bruce A. [3 ]
Gilbert, Jeremy D. [4 ]
Zinman, Bernard [5 ]
机构：
[1] LMC Diabet & Endocrinol, Thornhill, ON, Canada
[2] Univ Toronto, St Michaels Hosp, Li Ka Shing Knowledge Inst, Dept Surg,Div Cardiac Surg, Toronto, ON, Canada
[3] Univ Toronto, Mt Sinai Hosp, Dept Med, Div Endocrinol & Metab, Toronto, ON, Canada
[4] Sunnybrook Hlth Sci Ctr, Div Endocrinol & Metab, Toronto, ON, Canada
[5] Univ Toronto, Mt Sinai Hosp, Lunenfeld Tanenbaum Res Inst, Toronto, ON, Canada
来源：
CANADIAN JOURNAL OF DIABETES | 2017年 / 41卷 / 01期
关键词：
TYPE-2; DIABETES-MELLITUS; PANCREATIC ALPHA-CELLS; DAPAGLIFLOZIN ADD-ON; DOUBLE-BLIND; POSTPRANDIAL GLUCAGON; BETA-CELLS; METFORMIN; THERAPY; SAXAGLIPTIN; SECRETION;
D O I：
10.1016/j.jcjd.2016.08.001
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：6 / 9
页数：4
相关论文
共 50 条
  • [21] Sodium-glucose cotransporter 2 (SGLT2) inhibitor initiation and hepatocellular carcinoma prognosis
    Hendryx, Michael
    Dong, Yi
    Ndeke, Jonas M.
    Luo, Juhua
    PLOS ONE, 2022, 17 (09):
  • [22] Role of genetic variation in the human sodium-glucose cotransporter 2 gene (SGLT2) in glucose homeostasis
    Enigk, Uta
    Breitfeld, Jana
    Schleinitz, Dorit
    Dietrich, Kerstin
    Halbritter, Jan
    Fischer-Rosinsky, Antje
    Enigk, Beate
    Mueller, Ines
    Spranger, Joachim
    Pfeiffer, Andreas
    Stumvoll, Michael
    Kovacs, Peter
    Toenjes, Anke
    PHARMACOGENOMICS, 2011, 12 (08) : 1119 - 1126
  • [23] Sodium-Glucose Cotransporter 2 Inhibitors
    Erol, Cetin
    ANATOLIAN JOURNAL OF CARDIOLOGY, 2024, 28 (05): : 216 - 216
  • [24] Sodium-glucose cotransporter 2 (SGLT2) inhibitors in nephrolithiasis: should we "gliflozin" patients with kidney stone disease?
    de Carvalho, Mauricio
    Heilberg, Ita Pfeferman
    JORNAL BRASILEIRO DE NEFROLOGIA, 2024, 46 (03):
  • [25] The role of sodium-glucose cotransporter 2 (SGLT2) inhibitors in epicardial adipose tissue modulation: a meta-analysis
    Theofilis, P.
    Vlachakis, P. K.
    Antonopoulos, A. S.
    Sagris, M.
    Mantzouranis, E.
    Sakalidis, A.
    Oikonomou, E.
    Siasos, G.
    Tsioufis, K.
    Tousoulis, D.
    EUROPEAN HEART JOURNAL, 2024, 45
  • [26] Sodium-glucose cotransporter 2 (SGLT2) inhibitors-induced erythropoiesis and cardiovascular events in chronic kidney patients
    Marques Vidas, Maria De San Miguel
    Lopez, Paula
    Sanchez Briales, Paula
    Sanchez, Ana
    Lopez Illazquez, Maria Victoria
    Maria Portoles, Jose
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2024, 39 : I1043 - I1043
  • [27] Severe acute complications by sodium-glucose cotransporter-2 (sglt2) inhibitors: A real problem and not so infrecuent
    Trastoy, Olaia Diaz
    Sobrino, Paula Sanchez
    Iraeta, Antonia Lourdes Rego
    MEDICINA CLINICA, 2020, 155 (03): : 138 - 139
  • [28] Sodium-glucose cotransporter 2 (SGLT2) inhibitors-induced erythropoiesis and cardiovascular events in chronic kidney patients
    Vidas, Maria De San Miguel Marques
    Lopez, Paula
    Briales, Paula Sanchez
    Sanchez, Ana
    Illazquez, Maria Victoria Lopez
    Portoles, Jose Maria
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2024, 39
  • [29] Direct effect of sodium-glucose cotransporter 2 (SGLT2) inhibitors on cardiomyocyte function as a potential therapy for Phospholamban cardiomyopathy
    Hnatiuk, Anna
    Li, Alexander
    Staudt, David
    Serrano, Ricardo
    Mercola, Mark
    CIRCULATION RESEARCH, 2024, 135
  • [30] Prevention of cardiovascular disease and renal failure in type 2 diabetes: sodium-glucose cotransporter-2 (SGLT2) inhibitors
    O'Sullivan, Jack W.
    BMJ EVIDENCE-BASED MEDICINE, 2020, 25 (02) : 79 - 80
12345